Medicare negotiates lower prices on 15 popular medications. Will it save you money?
The Trump administration has successfully negotiated lower prices for 15 commonly used medications covered by Medicare, resulting in a projected savings of $12 billion. While this initiative is expected to reduce overall spending on these drugs by 44%, the impact on individual seniors may vary.
Medicare enrollees are already protected by a cap on drug costs, which limits their out-of-pocket expenses. However, the Centers for Medicare and Medicaid Services (CMS) announced that the new pricing agreement will save the 55 million individuals enrolled in the Part D pharmaceutical plan approximately $685 million. On average, this translates to savings of around $129 per Medicare beneficiary, with 5.3 million people using the discounted drugs.
Through the Inflation Reduction Act, Medicare was able to negotiate lower prices for these medications, which will go into effect in 2027 for Part D prescription plan participants. The discounts range from 38% to 85% off the list prices of the drugs, including well-known medications like Ozempic and Wegovy by Novo Nordisk, used for diabetes and weight loss, as well as treatments for asthma and prostate cancer.
Seniors have long been concerned about the rising cost of prescription drugs, with the Inflation Reduction Act also introducing a $2,000 out-of-pocket spending cap starting in 2025. This cap, adjusted annually for inflation, provides a safety net for Medicare enrollees, who will pay nothing for covered prescriptions once they reach the threshold.
While individual savings are significant, the lower drug prices will also benefit Medicare as a whole. Merith Basey, executive director of Patients For Affordable Drugs, emphasized that Medicare’s bargaining power plays a crucial role in lowering prices for expensive medications and ultimately funding the out-of-pocket cap for beneficiaries.
These negotiations represent a powerful tool in controlling drug prices and holding the pharmaceutical industry accountable, according to Basey. The recent deals negotiated by President Trump for specific drugs like Zepbound, Ozempic, and Wegovy further demonstrate the administration’s commitment to reducing prescription costs for Medicare and Medicaid beneficiaries.
It is important to note that the negotiated prices under the Inflation Reduction Act may differ from those negotiated under previous agreements. CMS stated that the pricing from the earlier deal is expected to supersede the prices stipulated in the IRA, but did not provide specific details on how the two programs will interact.
